Market Spotlight: Eating Disorders
Market Spotlight: Eating Disorders
$1,318.00
This Market Spotlight report covers the Eating Disorders market, comprising key marketed and pipeline drugs, clinical trials, probability of success, and a 10-year disease prevalence forecast, and as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the Eating Disorders market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, probability of success, a 10-year disease prevalence forecast, and as well as presenting drug-specific revenue forecasts.
Key Takeaways
- Worldwide, Datamonitor Healthcare estimates that in 2017, there were approximately 35.6 million prevalent cases of eating disorders in females aged 10–19 years, including 3.0 million cases of anorexia nervosa, 11.6 million cases of bulimia nervosa, and 14.3 million cases of binge eating disorder.
- In this demographic group, Datamonitor Healthcare forecasts the number of prevalent cases of eating disorders to increase to 38.1 million by 2026.
- Edgemont’s Fluoxetine Tablets, Eli Lilly’s Prozac, and Takeda’s Vyvanse are the only FDA-approved drugs for eating disorders. These drugs are administered via the oral route, with Vyvanse also available in an intranasal formulation.
- There are only three industry-sponsored drugs in active clinical development for eating disorders, with one drug in Phase I and two in Phase II.
- Therapies in active clinical development for eating disorders target hypocretin/orexin receptor, ghrelin receptor, and melanocortin receptors. These therapies are being tested as oral and subcutaneous formulations.
- The overall likelihood of approval of a Phase I eating disorders asset is 8.9%, and the average probability a drug advances from Phase III is 66.7%. Drugs, on average, take 5.8 years from Phase I to approval, compared to 9.6 years in the overall psychiatry space.
- All of the clinical trials for eating disorders have been in Phase III.
- The US leads in terms of the number of eating disorders clinical trials globally. Clinical trial activity in the eating disorders space consists entirely of completed trials. Johnson & Johnson has the highest number of completed clinical trials for eating disorders, with two trials.
- Johnson & Johnson leads industry sponsors with the highest number of Phase III clinical trials for eating disorders
CONTENTS
5 OVERVIEW
6 KEY TAKEAWAYS
7 DISEASE BACKGROUND
7 Subtypes
8 TREATMENT
8 Psychotherapy
8 Medications
9 EPIDEMIOLOGY
18 MARKETED DRUGS
20 PIPELINE DRUGS
24 PROBABILITY OF SUCCESS
25 REVENUE OPPORTUNITY
26 CLINICAL TRIAL LANDSCAPE
27 Sponsors by status
28 Sponsors by phase
30 BIBLIOGRAPHY
31 APPENDIX
LIST OF FIGURES
11 Figure 1: Trends in worldwide prevalent cases of eating disorders in females aged 10–19 years, 2017–26
20 Figure 2: Overview of pipeline drugs for eating disorders in the US
20 Figure 3: Pipeline drugs for eating disorders, by company
20 Figure 4: Pipeline drugs for eating disorders, by drug type
21 Figure 5: Pipeline drugs for eating disorders, by classification
24 Figure 6: Probability of success in the eating disorders pipeline
26 Figure 7: Clinical trials in eating disorders
26 Figure 8: Top 10 drugs for clinical trials in eating disorders
27 Figure 9: Top 10 companies for clinical trials in eating disorders
27 Figure 10: Trial locations in eating disorders
28 Figure 11: Eating disorders trials status
29 Figure 12: Eating disorders trials sponsors, by phase
LIST OF TABLES
10 Table 1: Worldwide prevalent cases of eating disorders in females aged 10–19 years, 2017–26
12 Table 2: Prevalent cases of eating disorders in females aged 10–19 years in Africa, 2017–26
13 Table 3: Prevalent cases of eating disorders in females aged 10–19 years in Asia, 2017–26
14 Table 4: Prevalent cases of eating disorders in children aged 10–19 years in Latin America and the Caribbean, 2017–26
15 Table 5: Prevalent cases of eating disorders in children aged 10–19 years in Northern America, 2017–26
16 Table 6: Prevalent cases of eating disorders in children aged 10–19 years in Oceania, 2017–26
17 Table 7: Prevalent cases of eating disorders in all ages in Europe, 2017–26
19 Table 8: Marketed drugs for eating disorders
22 Table 9: Pipeline drugs for eating disorders in the US
25 Table 10: Historical global sales, by drug ($m), 2016–20
25 Table 11: Forecasted global sales, by drug ($m), 2021–25
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Disease Analysis: Meningococcal Vaccines 
Sign up to the